➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
Dow
Moodys
AstraZeneca

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Patent: 10,094,836

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,094,836
Title:SLCO1B3 genotype
Abstract: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
Inventor(s): Figg; William D. (Fairfax, VA), Sparreboom; Alex (Memphis, TN), Hamada; Akinobu (Tokyo, JP), Price; Douglas K. (Fairfax, VA), Sissung; Tristan M. (Annandale, VA)
Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)
Application Number:12/522,480
Patent Claims:see list of patent claims

Details for Patent 10,094,836

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) 2027-01-08 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) 2027-01-08 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) 2027-01-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.